Literature DB >> 7929062

Requirement for kinase activity of CD4-associated p56lck in antibody-triggered T cell signal transduction.

K Chu1, D R Littman.   

Abstract

The lymphoid-specific Src family protein tyrosine kinase p56lck (Lck) is non-covalently associated with the cytoplasmic tail of CD4 and has an essential role in T cell activation. Engagement of ligand by the T cell antigen receptor (TCR) is followed by rapid tyrosine phosphorylation of several cellular proteins, including phospholipase C gamma 1 (PLC) and the TCR-associated CD3 zeta polypeptides. Tyrosine phosphorylation of PLC gamma 1 results in activation of PLC and subsequent phosphatidylinositol turnover. We have studied the effects of the CD4-associated Lck molecule on TCR-mediated activation of the protein tyrosine kinase (PTK) pathway in a murine T cell hybridoma. Antibodies against CD3 elicited the expected PTK activation, which was enhanced upon co-cross-linking of CD4. In contrast, anti-TCR-alpha beta antibodies had no effect on the PTK pathway unless CD4 was co-cross-linked. Antibody cross-linking of CD4 alone failed to induce the same pattern of tyrosine phosphorylation. Similar results were obtained when a chimeric protein consisting of the extracellular and transmembrane domains of CD4 linked to the intracellular Lck molecule was used in place of CD4. The tyrosine kinase activity of Lck was essential for the activity of the chimeric protein. Cross-linking of the CD4/Lck chimera to a CD8/zeta chimeric molecule also facilitated induction of the PTK pathway with anti-CD8 antibodies. Moreover, the interaction of the two chimeric proteins, either in vitro or in vivo, resulted in tyrosine phosphorylation of CD8/zeta. The effects of CD4/Lck on tyrosine phosphorylation and activation of PLC correlated well with the effects on PTK activation. Our results suggest that the Lck molecule positively regulates the TCR-coupled PTK pathway by phosphorylating tyrosines on the TCR-associated CD3 zeta polypeptides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929062

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  ITAM-mediated signaling by the T-cell antigen receptor.

Authors:  Paul E Love; Sandra M Hayes
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-28       Impact factor: 10.005

2.  Unaltered negative selection and Treg development of self-reactive thymocytes in TCR transgenic Fyn-deficient mice.

Authors:  Alusha A Mamchak; Christine B F Thien; Samantha A Dagger; Julia Lyandres; Shuwei Jiang; Wallace Y Langdon; Anthony L DeFranco
Journal:  Eur J Immunol       Date:  2010-02       Impact factor: 5.532

3.  Programmed Death-1 Inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4+ T Cell Proliferation.

Authors:  Lindsay J Celada; Joseph E Rotsinger; Anjuli Young; Guzel Shaginurova; Debresha Shelton; Charlene Hawkins; Wonder P Drake
Journal:  Am J Respir Cell Mol Biol       Date:  2017-01       Impact factor: 6.914

4.  Fas (CD95) expression and death-mediating function are induced by CD4 cross-linking on CD4+ T cells.

Authors:  J Desbarats; J H Freed; P A Campbell; M K Newell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

5.  Normal development and activation but altered cytokine production of Fyn-deficient CD4+ T cells.

Authors:  Alusha A Mamchak; Brandon M Sullivan; Baidong Hou; Linda M Lee; Julia K Gilden; Matthew F Krummel; Richard M Locksley; Anthony L DeFranco
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

6.  Cell-cycle arrest and apoptosis hypersusceptibility as a consequence of Lck deficiency in nontransformed T lymphocytes.

Authors:  B K al-Ramadi; H Zhang; A L Bothwell
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

7.  Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains.

Authors:  Gustavo Del Real; Sonia Jiménez-Baranda; Rosa Ana Lacalle; Emilia Mira; Pilar Lucas; Concepción Gómez-Moutón; Ana C Carrera; Carlos Martínez-A; Santos Mañes
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.